drugset
drugset / Trial / NCT06629597

A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma

NCT06629597 ↗

Phase 3 Recruiting 400 enrolled MediLink Therapeutics (Suzhou) Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

This study was designed to compare the efficacy and safety of YL201 with Investigator's choice of chemotherapy in subjects with recurrent or metastatic nasopharyngeal carcinoma who have failed prior PD-(L)1 inhibitor and at least two lines of chemotherapy.

Timeline

Start
2024-12-31
Primary completion
2027-12-01
Completion
2028-12-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Capecitabine Small molecule 1000 mg/m2 Oral
Comparator Docetaxel Small molecule 75 mg/m2 Intravenous
Comparator Gemcitabine Small molecule 1000 mg/m2 Intravenous
Subject YL201 Other / unclassified — Intravenous

Indications

nasopharyngeal carcinoma